Chronic pain biotech Ambros Therapeutics emerges with $125M and Vivek...
A California biotech launched on Tuesday morning to try to bring a niche pain drug, approved in Italy for more than a decade, to the US. Investors are pumping $125 million into the company, called ...
View ArticleCalming nerves with a hot wearable
Hey, it’s Shelby. I’m back from maternity leave, during which I surprised myself by embracing health tech more than ever before. I’m admittedly a technology skeptic. I’ve always preferred in-person...
View ArticleOrsoBio obesity data; Monte Rosa's prostate cancer pill; Development pacts...
Plus, news about: Hansoh, Caris-Genentech, Royalty, LIB, Greenwich LifeSciences, Gubra, J&J, Sprout, Tiziana and Vor. 💊 OrsoBio’s early obesity data: When combined with Lilly’s tirzepatide,...
View ArticleJ&J backs financing round for Stanford CAR-T cell therapy spinout Link Cell
Link Cell Therapies launched Monday with a $60 million Series A round to fund the creation of the next wave of CAR-T therapies. The startup plans to go after the treatment of solid tumors, where ...
View ArticlePfizer bets big on obesity to offset major patent cliff
Pfizer said it plans to start 15 new studies in obesity next year, many of them in Phase 3, as it seeks to replace about $17 billion in lost revenue by the end of the ...
View ArticleNektar's immunology drug misses in Phase 2b, execs cite enrollment errors
Nektar Therapeutics said a Phase 2b study for its lead immunology drug failed in severe alopecia, but executives blamed the miss on trial enrollment errors and plan to advance the program into pivotal...
View ArticleMythic Therapeutics shuts down, ends ADC trial as funding dries up
Mythic Therapeutics has ended operations, terminating its sole clinical trial after failing to raise enough money to move forward, Endpoints News has learned. The Boston-area biotech "pursued various...
View ArticleVerge Genomics' ALS drug fails as biotech shifts to partner model
Verge Genomics' sole clinical-stage drug has failed, and the California biotech will shift to a partnership model for its AI-driven discovery platform, Endpoints News has learned. The biotech's...
View ArticleMakary walks back talk of Covid-19 vaccine risk amid internal FDA debate
FDA Commissioner Marty Makary offered a softer version of the FDA's view of Covid-19 vaccines than emerged in a recent internal memo, saying that the agency wasn't planning to add its most severe...
View ArticleDBV charts new path to market peanut allergy patch after Phase 3 success
DBV Technologies said its peanut allergy patch succeeded in a Phase 3 trial, setting the company up for another FDA submission after a drawn-out saga with regulators. The trial enrolled more than 650...
View ArticleHarbour makes $90M upfront deal with Bristol Myers for new antibodies
Bristol Myers Squibb is the latest large pharma to tap into the speed and efficiency of drug R&D in China. The New York drug giant will pay as much as $90 million in upfront and ...
View ArticleGSK wins FDA approval for long-acting asthma drug
GSK secured FDA approval for an inflammatory disease drug that it says could reach £3 billion ($4 billion) in peak sales. The agency greenlit depemokimab as an add-on treatment for patients aged 12...
View ArticleHansa’s enzyme therapy flunks Phase 3 trial in rare kidney disease
Hansa Biopharma said Tuesday that its IgG-targeting treatment candidate has failed a late-stage study in a rare type of kidney disease due to an overperforming control arm. The Swedish biotech’s...
View ArticleAddition Therapeutics raises $106.5M for all RNA 'jumping gene' therapies
The challenging and competitive field of gene insertion has another well-funded contender. Addition Therapeutics, a startup based on research from the University of California, Berkeley, has raised...
View ArticlePost-Hoc Live: Endpoints winners and losers list for 2025
The Endpoints Winners and Losers list is back — and we're bringing it to Post-Hoc Live on Thursday (that's tomorrow) at 12 p.m. ET. The list is our now-annual tradition, tracking who was up and who was...
View ArticleAI biotech preview of 2026: Clinic takes center stage
Chris Bahl saw the writing on the wall for his new AI startup in the final weeks of 2022: Molecules would matter more than models. A pair of preprints had just come out, both showing ...
View ArticleVir licensing deal; Cytokinetics wins China nod; Vistagen's social anxiety fail
Plus, news about Neurocrine, TargED, T-CURX, Immunome and Kodiak: 🤝 Vir Biotechnology's licensing deal: An affiliate of Norgine Pharma will take the commercial rights to the experimental chronic...
View ArticleNovo Nordisk hit with FDA warning letter over acquired Catalent factory
The FDA wants Novo Nordisk to analyze all sites it bought from Catalent last year, according to a warning letter the agency sent to the drugmaker over its troubled factory in Bloomington, IN. The ...
View ArticleRTW's Yarrow to go public in reverse merger with Vyne Therapeutics
Vyne Therapeutics will hand its Nasdaq spot to RTW's Yarrow Bioscience in a reverse merger that will also bring a $200 million cash infusion into the biotech. The all-stock transaction
View ArticlePadcev-Keytruda combination notches another bladder cancer win
Pfizer, Astellas and Merck announced Wednesday that the combination of Padcev and Keytruda helped certain bladder cancer patients live longer in a Phase 3 trial, and plan to take the regimen to...
View Article